Mark R. Somerfield

41.8k total citations · 24 hit papers
141 papers, 27.5k citations indexed

About

Mark R. Somerfield is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark R. Somerfield has authored 141 papers receiving a total of 27.5k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 45 papers in Cancer Research and 29 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark R. Somerfield's work include Breast Cancer Treatment Studies (42 papers), Economic and Financial Impacts of Cancer (15 papers) and Colorectal Cancer Treatments and Studies (13 papers). Mark R. Somerfield is often cited by papers focused on Breast Cancer Treatment Studies (42 papers), Economic and Financial Impacts of Cancer (15 papers) and Colorectal Cancer Treatments and Studies (13 papers). Mark R. Somerfield collaborates with scholars based in United States, Canada and United Kingdom. Mark R. Somerfield's co-authors include Daniel F. Hayes, Gary H. Lyman, Thomas J. Smith, Robert C. Bast, J. Milburn Jessup, Robert Mennel, Al B. Benson, Peter M. Ravdin, Herbert A. Fritsche and David G. Pfister and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Mark R. Somerfield

138 papers receiving 26.6k citations

Hit Papers

American Society of Clinical Oncology 2007 Update of Reco... 2000 2026 2008 2017 2007 2005 2006 2003 2004 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
    2007 1.7k citations Lyndsay N. Harris, Herbert A. Fritsche et al. Journal of Clinical Oncology profile →
  2. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
    2005 1.4k citations Gary H. Lyman, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  3. ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal Cancer
    2006 1.2k citations Mark R. Somerfield, Daniel F. Hayes et al. Journal of Clinical Oncology profile →
  4. American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
    2003 1.2k citations Thomas J. Smith, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  5. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer
    2004 1.1k citations Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  6. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
    2015 968 citations Gary H. Lyman, Kari Bohlke et al. Journal of Clinical Oncology profile →
  7. American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care
    2012 950 citations Thomas J. Smith, Sarah Temin et al. Journal of Clinical Oncology profile →
  8. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
    2009 915 citations Mark R. Somerfield, Daniel F. Hayes et al. Journal of Clinical Oncology profile →
  9. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology
    2018 904 citations Mark R. Somerfield, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  10. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
    2011 827 citations Ethan Basch, Ann Alexis Prestrud et al. Journal of Clinical Oncology profile →
  11. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
    2007 723 citations Gary H. Lyman, Alok A. Khorana et al. Journal of Clinical Oncology profile →
  12. 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*
    2001 660 citations Robert C. Bast, Peter M. Ravdin et al. Journal of Clinical Oncology profile →
  13. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
    2000 629 citations Thomas J. Smith, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  14. American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
    2010 612 citations Harold J. Burstein, Ann Alexis Prestrud et al. Journal of Clinical Oncology profile →
  15. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    2021 592 citations Larissa A. Korde, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  16. American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects
    2007 561 citations Karen L. Hagerty, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  17. Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation
    2014 531 citations Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  18. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006
    2006 516 citations Mark G. Kris, Paul J. Hesketh et al. Journal of Clinical Oncology profile →
  19. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
    2011 399 citations Sarah Temin, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  20. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
    2017 397 citations Paul J. Hesketh, Mark G. Kris et al. Journal of Clinical Oncology profile →
  21. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
    2017 375 citations Gary H. Lyman, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  22. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
    2023 251 citations Antonio C. Wolff, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  23. Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
    2024 67 citations Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  24. Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update
    2025 18 citations Ko Un Park, Mark R. Somerfield et al. Journal of Clinical Oncology profile →

Peers

Mark R. Somerfield
J.W.W. Coebergh Netherlands
Hyman B. Muss United States
Lynn A. G. Ries United States
Richard Gray United Kingdom
Alfred I. Neugut United States
Deborah Schrag United States
Richard L. Schilsky United States
Carol DeSantis United States
Angela B. Mariotto United States
Roger A’Hern United Kingdom
J.W.W. Coebergh Netherlands
Mark R. Somerfield
Citations per year, relative to Mark R. Somerfield Mark R. Somerfield (= 1×) peers J.W.W. Coebergh

Countries citing papers authored by Mark R. Somerfield

Since Specialization
Citations

This map shows the geographic impact of Mark R. Somerfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark R. Somerfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark R. Somerfield more than expected).

Fields of papers citing papers by Mark R. Somerfield

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark R. Somerfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark R. Somerfield. The network helps show where Mark R. Somerfield may publish in the future.

Co-authorship network of co-authors of Mark R. Somerfield

This figure shows the co-authorship network connecting the top 25 collaborators of Mark R. Somerfield. A scholar is included among the top collaborators of Mark R. Somerfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark R. Somerfield. Mark R. Somerfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Ko Un, Mark R. Somerfield, Muriel Brackstone, et al.. (2025). Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 43(14). 1720–1741. 18 indexed citations breakdown →
2.
Park, Ko Un, Raymond B. Mailhot Vega, Jeffrey Hawley, et al.. (2025). Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice. OP2500447–OP2500447.
3.
Freedman, Rachel A., Jennifer L. Caswell‐Jin, Michael J. Hassett, et al.. (2024). Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology. 42(18). 2233–2235. 18 indexed citations
4.
Makhlin, Igor, Lesley Fallowfield, N. Lynn Henry, et al.. (2024). Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights. JCO Oncology Practice. 21(2). 140–144. 8 indexed citations
5.
Caswell‐Jin, Jennifer L., Rachel A. Freedman, Michael J. Hassett, et al.. (2024). Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights. JCO Oncology Practice. 21(3). 287–291. 4 indexed citations
6.
Wolff, Antonio C., Mark R. Somerfield, Mitch Dowsett, et al.. (2023). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update. Journal of Clinical Oncology. 41(22). 3867–3872. 251 indexed citations breakdown →
7.
8.
9.
Vikas, Praveen, Larissa A. Korde, Mark R. Somerfield, & Dawn L. Hershman. (2022). Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice. 18(9). 649–651. 6 indexed citations
10.
Korde, Larissa A., Mark R. Somerfield, Lisa A. Carey, et al.. (2021). Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology. 39(13). 1485–1505. 592 indexed citations breakdown →
11.
12.
Denduluri, Neelima, Mark R. Somerfield, Mariana Chávez‐MacGregor, et al.. (2020). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 39(6). 685–693. 76 indexed citations
13.
Visvanathan, Kala, Carol J. Fabian, Elissa Bantug, et al.. (2019). Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology. 37(33). 3152–3165. 117 indexed citations
14.
André, Fabrice, Nofisat Ismaila, N. Lynn Henry, et al.. (2019). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx. Journal of Clinical Oncology. 37(22). 1956–1964. 151 indexed citations
15.
Lyman, Gary H., Kari Bohlke, Alok A. Khorana, et al.. (2015). Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. Journal of Clinical Oncology. 33(6). 654–656. 968 indexed citations breakdown →
16.
Smith, Thomas J., Sarah Temin, Erin R. Alesi, et al.. (2012). American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care. Journal of Clinical Oncology. 30(8). 880–887. 950 indexed citations breakdown →
17.
Basch, Ethan, Ann Alexis Prestrud, Paul J. Hesketh, et al.. (2011). Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. 29(31). 4189–4198. 827 indexed citations breakdown →
18.
Rizzo, J. Douglas, Mark R. Somerfield, Karen L. Hagerty, et al.. (2007). Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update. Journal of Clinical Oncology. 26(1). 132–149. 230 indexed citations
19.
Harris, Lyndsay N., Herbert A. Fritsche, Robert Mennel, et al.. (2007). American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. Journal of Clinical Oncology. 25(33). 5287–5312. 1670 indexed citations breakdown →
20.
Somerfield, Mark R., Jeff Sloan, & Charles L. Loprinzi. (1999). Wherefore global quality-of-life assessment? [6] (multiple letters). Journal of Clinical Oncology. 17(2). 738–740. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.W.W. Coebergh Breakdown of academic impact, for papers by Hyman B. Muss Breakdown of academic impact, for papers by Lynn A. G. Ries Breakdown of academic impact, for papers by Richard Gray Breakdown of academic impact, for papers by Alfred I. Neugut Breakdown of academic impact, for papers by Deborah Schrag Breakdown of academic impact, for papers by Richard L. Schilsky Breakdown of academic impact, for papers by Carol DeSantis Breakdown of academic impact, for papers by Angela B. Mariotto Breakdown of academic impact, for papers by Roger A’Hern
Rankless by CCL
2026